Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02844543 · ClinicalTrials.gov registry record · NA

EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1

A NA study, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
155
Enrollment target

NCT02844543: Completed NA study, sponsored by Stanford University.

NCT02844543 is a NA study that has completed, run by Stanford University. The registered enrollment target is 155 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02844543, a NA study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
155 participants
Enrollment target

Study Summary

This study will assess the effects of exercise and non-concussive bodily contact on eye-tracking scores collected by the EYE-SYNC eye-tracking device.

Primary Outcome

The EYE-SYNC test was performed before and after practice to analyze the effect of exercise and sub-concussive impact. The movement of eye was tracked using EYE-SYNC. The data were recorded in a surface tablet connected to EYE-SYNC. Phase error is defined as the difference in degrees between movement of the target and the movement of the eye. Positive values indicate the eye is ahead of the target; negative values indicate the eye is behind the target.

Interventions

  • DEVICE EYE-SYNC eye-tracking device
  • OTHER SCAT-3
  • DEVICE Desktop Eye-Tracker

Trial Details

FieldValue
Enrollment Target 155 participants
Start Date 2016-01
Est. Completion 2016-12
Phase NA
Stanford University

1,744 total trials

What the finished NCT02844543 record still lists

NCT02844543 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 3 interventions - of which EYE-SYNC eye-tracking device is the first listed.

NCT02844543 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02844543 about?

NCT02844543 is a clinical study titled "EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1". This study will assess the effects of exercise and non-concussive bodily contact on eye-tracking scores collected by the EYE-SYNC eye-tracking device.

What is the current status of trial NCT02844543?

This trial is currently completed. It is a NA study. The enrollment target is 155 participants. The study started on 2016-01. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02844543?

The interventions under investigation include: EYE-SYNC eye-tracking device (DEVICE), SCAT-3 (OTHER), Desktop Eye-Tracker (DEVICE).

Who is sponsoring clinical trial NCT02844543?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02844543's enrollment target sits among peer trials

155 656th of 2000 higher than 1,345 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03223610 · 155 participants · Phase 1

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  • NCT05072483 · 155 participants

    Natural History Study of CADASIL

  • NCT05086497 · 155 participants · NA

    WBSI Guided Personalized Delivery of TTFields

  • NCT05412069 · 155 participants · NA

    Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02844543, the US trial registry maintained by the National Library of Medicine. NCT02844543 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.